SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
| Xenpozyme | 20 mg | Powder for concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 17896.60 | Biological · Prescription | Sanofi B.V | Valid |
Indications — CHI Daman Drug Formulary
ACID SPHINGOMYELINASE DEFICIENCY
EMA European Union — centrally authorised medicines
Xenpozyme Sanofi B.V. · Authorised · authorised 24 Jun 2022 · ATC A16AB25
Therapeutic indication (EMA)
Xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
| XENPOZYME | 02545721 | 20 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANOFI-AVENTIS CANADA INC |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.